Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report By Sample Type (Blood Sample, Others), By Biomarker, By Technology, By Application, By End Use, By Region – Market Forecast, 2025–2034

The global liquid biopsy market size is expected to reach USD 36.59 billion by 2034, according to a new study by Polaris Market Research. The report “Liquid Biopsy Market Size, Share, Trends, Industry Analysis Report By Sample Type (Blood Sample, Others), By Biomarker, By Technology, By Application, By End Use, By Region – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

A liquid biopsy is an advanced, noninvasive diagnostic test that analyzes biological markers from a simple fluid sample, such as blood or urine. Unlike a traditional tissue biopsy, which requires a surgical procedure, this method allows for a safer and more convenient way to gather information about a disease. It primarily focuses on detecting tiny fragments of DNA, RNA, and proteins shed by tumors into the bloodstream, offering doctors a detailed look at a tumor's genetic makeup and progression over time. This makes it an especially powerful tool for cancer diagnosis, monitoring, and treatment planning.

The market is driven by the growing need for less invasive and more accurate diagnostic tools, especially with the rising number of cancer cases worldwide. The push for personalized medicine has also been a major influence, as liquid biopsies can help identify specific genetic mutations that inform a patient's treatment plan. As technologies become more refined and affordable, the application of liquid biopsies is expanding beyond cancer biopsy into areas such as reproductive health and disease monitoring, further fueling the liquid biopsy market expansion.

Liquid Biopsy Market Report Highlights

Based on sample type, the blood sample segment held the largest share in 2024, owing to its convenience and the wide range of biomarkers it provides.

In terms of biomarker, the circulating tumor DNA (ctDNA) segment held the largest share because of its high sensitivity and specificity.

By technology, the multi-gene parallel analysis (NGS) segment held the largest share due to its ability to analyze multiple genes at once. It is also commonly used for advanced cancer diagnostics and personalized treatment planning.

By application, the cancer segment held the largest share. Liquid biopsies are highly valuable in oncology for a wide range of uses, including initial diagnosis, selecting the most effective personalized therapies, and monitoring a patient's response to treatment..

By end use, the hospitals and laboratories segment held the largest share because they are widely utilized for cancer diagnosis and treatment, and have the necessary infrastructure.

By region, North America held the largest share in 2024 in the market due to its well-established healthcare system and presence of advanced diagnostics. Asia Pacific is one of the fastest-growing regional markets. Increasing healthcare spending and a growing focus on improving medical infrastructure are propelling the market growth in the region.

A few key players in the liquid biopsy market include F. Hoffmann-La Roche Ltd; Illumina, Inc.; Guardant Health, Inc.; Bio-Rad Laboratories, Inc.; Thermo Fisher Scientific, Inc.; Natera, Inc.; Exact Sciences Corporation; Adaptive Biotechnologies Corporation; Myriad Genetics, Inc.; and NeoGenomics Laboratories, Inc.

Polaris Market Research has segmented the liquid biopsy market report based on sample type, biomarker, technology, application, end use, and region:

By Sample Type Outlook (Revenue – USD Billion, 2020–2034)

Blood Sample

Others

By Biomarker Outlook (Revenue – USD Billion, 2020–2034)

Circulating Tumor Cells (CTCs)

Circulating Tumor DNA (ctDNA)

Extracellular Vehicles (EVs)

Others

By Technology Outlook (Revenue – USD Billion, 2020–2034)

Multi-gene parallel Analysis (NGS)

Single Gene Analysis (PCR Microarrays)

By Application Outlook (Revenue – USD Billion, 2020–2034)

Cancer

Reproductive Health

Others

By End Use Outlook (Revenue – USD Billion, 2020–2034)

Hospitals and Laboratories

Specialty Clinics

Academic and Research Centers

Others

By Regional Outlook (Revenue – USD Billion, 2020–2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America Show more